NHAS
MGX icon

Novo Holdings A/S’s Metagenomi Therapeutics MGX Stock Holding History

Novo Holdings A/S’s Portfolio MGX Stock Details MGX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-1,800,000
Closed -$3.91M – 40
2024
Q3 		$3.91M Hold
1,800,000
– – 0.19% 32
2024
Q2 		$7.34M Buy
1,800,000
+60,825
+3% +$418K 0.4% 33
2024
Q1 		$18.3M Buy
+1,739,175
New +$20M 1.27% 26

Other funds holding MGX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SVGI
Sozo Ventures GP II Redwood City, California $1.33M AUM 9.22% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM

Novo Holdings A/S's MGX Position: Q4 2024 in Review

Novo Holdings A/S sold out of Metagenomi Therapeutics (MGX) in Q4 2024, closing a stake of 1,800,000 shares — an estimated $3.91M sold.

Novo Holdings A/S first reported a position in MGX in Q1 2024 and held it in 3 quarters. The position peaked at $18.3M in Q1 2024. 77 funds tracked by Wall St. Rank hold MGX as of Q4 2024.

  • Novo Holdings A/S reported no remaining Metagenomi Therapeutics position as of Q4 2024 after selling out during the quarter.
  • Novo Holdings A/S sold 1,800,000 Metagenomi Therapeutics shares in Q4 2024, an estimated $3.91M.
  • Novo Holdings A/S first reported a position in Metagenomi Therapeutics in Q1 2024 and held it in 3 quarters.
  • Novo Holdings A/S's Metagenomi Therapeutics position peaked at $18.3M in Q1 2024.
  • 77 funds tracked by Wall St. Rank held Metagenomi Therapeutics as of Q4 2024.

Based on Novo Holdings A/S's 13F filing for Q4 2024, filed 14 Feb 2025.